Sort   by:  
 Page size 
ProteomicsUse of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signaling networks using SILAC-based phosphoproteomics_C4PR
Polo-like kinase 4 (PLK4) is the master regulator of centriole duplication in metazoan organisms. Catalytic activity and protein turnover of PLK4 are tightly coupled in human cells, since changes in PLK4 concentration and catalysis have profound effects on centriole duplication and supernumerary cen...
ORGANISM(S): Homo sapiens (Human) 
2021-06-14 | PXD018704 | Pride
Mass spectrometry Centrinone  phosphoproteomics Inhibitor Phosphorylation  substrate Plk4 
UnknownEffects of the PLK4 inhibitor Centrinone on the biological behaviors of acute myeloid leukemia cell lines.
Not available
S-EPMC9424683 | biostudies-literature
UnknownAnticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells.
Not available
S-EPMC7519924 | biostudies-literature
UnknownUse of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.
Not available
S-EPMC7338032 | biostudies-literature
UnknownDefect of IL17 Signaling, but Not Centrinone, Inhibits the Development of Psoriasis and Skin Papilloma in Mouse Models.
Not available
S-EPMC9405709 | biostudies-literature
TranscriptomicsPLK inhibitors identified by high content phenotypic screening promote maturation of human iPSC-derived cardiomyocytes
We performed RNA-Seq analysis of human pluripotent stem cells derived cardiomyocytes (hPSC-CMs) which were treated with Centrinone or Volasertib for 14 days to investigate the moleclular mechanism of inhibiting L-type calcium channel (LTCC) to promote cardiomyocyte proliferation.
ORGANISM(S): Homo sapiens 
2022-03-06 | GSE197835 | GEO
UnknownPLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
Not available
S-EPMC10292002 | biostudies-literature
UnknownEvaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer.
Not available
S-EPMC6540285 | biostudies-literature
UnknownCell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4.
Not available
S-EPMC4764081 | biostudies-literature
Unknown53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration.
Not available
S-EPMC4949453 | biostudies-literature
Sort   by:  
 Page size